Bankless co-founder David Hoffman posted on the X platform that after liquidating ETH, he immediately invested about 50% of the funds into VVV, NEAR, ZEC, and HYPE; the remaining 50% of the funds will be gradually invested as cash reserves through dollar-cost averaging, and has been fully used to buy LIT.
On May 21, Bankless co-founder David Hoffman announced that he had liquidated all ETH. He then posted a detailed explanation of the reasons for liquidating Ethereum spot, emphasizing that this decision was not made on a whim.
David stated that the grand narrative of "ETH is money" has not failed, but has been fully priced and played out to its rightful conclusion— the Ethereum network has achieved a valuation that matches its current accomplishments, but the ETH asset itself is unlikely to be repriced by the market, whether upwards or downwards. He remains extremely optimistic about the Ethereum network, believing that the ecosystem will be exceptionally prosperous, but only a small portion of these successes will continue to be reflected in the price of ETH.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.






Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.









Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.